{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:16:23Z","timestamp":1706174183488},"reference-count":171,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2023-0209_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Antinuclear antibodies (ANA) are important for the diagnosis of various autoimmune diseases. ANA are usually detected by indirect immunofluorescence assay (IFA) using HEp-2 cells (HEp-2 IFA). There are many variables influencing HEp-2 IFA results, such as subjective visual reading, serum screening dilution, substrate manufacturing, microscope components and conjugate. Newer developments on ANA testing that offer novel features adopted by some clinical laboratories include automated computer-assisted diagnosis (CAD) systems and solid phase assays (SPA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0209_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A group of experts reviewed current literature and established recommendations on methodological aspects of ANA testing. This process was supported by a two round Delphi exercise. International expert groups that participated in this initiative included (i) the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group \u201cAutoimmunity Testing\u201d; (ii) the European Autoimmune Standardization Initiative (EASI); and (iii) the International Consensus on ANA Patterns (ICAP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0209_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 35 recommendations\/statements related to (i) ANA testing and reporting by HEp-2 IFA; (ii) HEp-2 IFA methodological aspects including substrate\/conjugate selection and the application of CAD systems; (iii) quality assurance; (iv) HEp-2 IFA validation\/verification approaches and (v) SPA were formulated. Globally, 95% of all submitted scores in the final Delphi round were above 6 (moderately agree, agree or strongly agree) and 85% above 7 (agree and strongly agree), indicating strong international support for the proposed recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0209_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These recommendations are an important step to achieve high quality ANA testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2023-0209","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T18:51:04Z","timestamp":1680115864000},"page":"1167-1198","source":"Crossref","is-referenced-by-count":6,"title":["Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP"],"prefix":"10.1515","volume":"61","author":[{"given":"Carolien","family":"Bonroy","sequence":"first","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"},{"name":"Department of Laboratory Medicine , University Hospital Ghent , Ghent , Belgium"}]},{"given":"Martine","family":"Vercammen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AZ Sint-Jan , Brugge , Belgium"},{"name":"Research Group REIM, Vrije Universiteit Brussel , Brussels , Belgium"}]},{"given":"Walter","family":"Fierz","sequence":"additional","affiliation":[{"name":"Schweizerischer Verband der Diagnostikindustrie (SVDI-ASID) , Bern , Switzerland"}]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8742-9931","authenticated-orcid":false,"given":"Luis E.C.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo , Sao Paulo , Brazil"},{"name":"Immunology Division, Fleury Medicine and Health Laboratories , Sao Paulo , Brazil"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-3462-7288","authenticated-orcid":false,"given":"Lieve","family":"Van Hoovels","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , OLV Hospital , Aalst , Belgium"},{"name":"Department of Microbiology, Immunology and Transplantation , KU Leuven , Leuven , Belgium"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[{"name":"Immunology and Allergology Laboratory, S. Giovanni di Dio Hospital , Florence , Italy"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[{"name":"Department of Medicine , Cumming School of Medicine, University of Calgary , Calgary , AB , Canada"}]},{"given":"Dimitrios","family":"Bogdanos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology , Faculty of Medicine, School of Health Sciences, University of Thessaly, University General Hospital of Larissa , Larissa , Greece"}]},{"given":"Ana","family":"Kozmar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics , University Hospital Centre Zagreb , Zagreb , Croatia"}]},{"given":"Benoit","family":"Nespola","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology, H\u00f4pitaux Universitaires de Strasbourg , Strasbourg , France"}]},{"given":"Sylvia","family":"Broeders","sequence":"additional","affiliation":[{"name":"Quality of Laboratories, Sciensano , Ixelles , Belgium"}]},{"given":"Dina","family":"Patel","sequence":"additional","affiliation":[{"name":"UK NEQAS Immunology, Immunochemistry & Allergy, Sheffield Teaching Hospitals , Sheffield , UK"}]},{"given":"Manfred","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Rheumatology Laboratory , Medical University of Innsbruck , Innsbruck , Austria"}]},{"given":"Bing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , P.R. China"}]},{"given":"Eric Y.T.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology , Queen Mary Hospital , Hong Kong , P.R. China"}]},{"given":"Raivo","family":"Uibo","sequence":"additional","affiliation":[{"name":"Department of Immunology , Medical Faculty, University of Tartu , Tartu , Estonia"}]},{"given":"Anna-Maija","family":"Haapala","sequence":"additional","affiliation":[{"name":"Department of Immunology , Fimlab Laboratories , Tampere , Finland"}]},{"given":"Lucile","family":"Musset","sequence":"additional","affiliation":[{"name":"Department of Immunology , Assistance Publique-H\u00f4pitaux de Paris, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}]},{"given":"Ulrich","family":"Sack","sequence":"additional","affiliation":[{"name":"Medical Faculty, Leipzig University , Leipzig , Germany"}]},{"given":"Gabor","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Faculty of Medicine, University of Debrecen , Debrecen , Hungary"}]},{"given":"Tatjana","family":"Sundic","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine , Haugesund Hospital, Helse Fonna , Haugesund , Norway"}]},{"given":"Katarzyna","family":"Fischer","sequence":"additional","affiliation":[{"name":"Individual Laboratory for Rheumatologic Diagnostics, Pomeranian Medical University in Szczecin , Szczecin , Poland"}]},{"given":"Maria-Jos\u00e9","family":"Rego de Sousa","sequence":"additional","affiliation":[{"name":"Immunopathology and Autoimmunity Department , Centro de Medicina Laboratorial Germano de Sousa , Lisbon , Portugal"}]},{"given":"Maria Luisa","family":"Vargas","sequence":"additional","affiliation":[{"name":"Immunology, Hospital Universitario de Badajoz , Badajoz , Spain"}]},{"given":"Catharina","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology Section\u00a0of\u00a0Infection and Immunology , Ume\u00e5 University , Ume\u00e5 , Sweden"}]},{"given":"Ingmar","family":"Heijnen","sequence":"additional","affiliation":[{"name":"Immunology, Laboratory Medicine, University Hospital Basel , Basel , Switzerland"}]},{"given":"Ignacio","family":"Garc\u00eda-De La Torre","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology , Hospital General de Occidente, Universidad de Guadalajara , Guadalajara , Mexico"}]},{"given":"Orlando Gabriel","family":"Carballo","sequence":"additional","affiliation":[{"name":"Laboratory of Immunology , Hospital Carlos G. Durand , Buenos Aires , Argentina"},{"name":"Department of Microbiology and Immunology , Instituto Universitario, Hospital Italiano de Buenos Aires , Buenos Aires , Argentina"}]},{"given":"Minoru","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Human, Information and Life Sciences , University of Occupational and Environmental Health , Kitakyushu , Japan"},{"name":"Department of Medicine , Kitakyushu Yahata-Higashi Hospital , Kitakyushu , Japan"}]},{"given":"Kyeong-Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Dong-A University College of Medicine , Busan , Republic of Korea"}]},{"given":"Edward K.L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Oral Biology , University of Florida , Gainesville , FL , USA"}]},{"ORCID":"http:\/\/orcid.org\/0000-0003-4007-6985","authenticated-orcid":false,"given":"Jan","family":"Damoiseaux","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory , Maastricht University Medical Center , Maastricht , The Netherlands"}]},{"given":"Marcos","family":"Lopez-Hoyos","sequence":"additional","affiliation":[{"name":"Immunology Service , University Hospital Marques de Valdecilla-IDIVAL, University of Cantabria , Santander , Spain"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation , KU Leuven , Leuven , Belgium"},{"name":"Department of Laboratory Medicine , University Hospital Leuven , Leuven , Belgium"}]}],"member":"374","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2024012310382636134_j_cclm-2023-0209_ref_001","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, De Langhe, E, Borghi, MO, Meroni, PL. Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol 2020;16:715\u201326. https:\/\/doi.org\/10.1038\/s41584-020-00522-w.","DOI":"10.1038\/s41584-020-00522-w"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_002","doi-asserted-by":"crossref","unstructured":"Martini, A, Ravelli, A, Avcin, T, Beresford, MW, Burgos-Vargas, R, Cuttica, R, et al.. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric Rheumatology international trials organization international consensus. J Rheumatol 2019;46:190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","DOI":"10.3899\/jrheum.180168"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_003","doi-asserted-by":"crossref","unstructured":"Vergani, D, Alvarez, F, Bianchi, FB, Cancado, EL, Mackay, IR, Manns, MP, et al.. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677\u201383. https:\/\/doi.org\/10.1016\/j.jhep.2004.08.002.","DOI":"10.1016\/j.jhep.2004.08.002"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_004","doi-asserted-by":"crossref","unstructured":"EASL, Beuers, U, Corpechot, C, Invernizzi, P, Jones, D, Marzioni, M, et al.. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_005","doi-asserted-by":"crossref","unstructured":"Francescantonio, PL, Cruvinel Wde, M, Dellavance, A, Andrade, LE, Taliberti, BH, von Muhlen, CA, et al.. IV Brazilian guidelines for autoantibodies on HEp-2 cells. Rev Bras Reumatol 2014;54:44\u201350. https:\/\/doi.org\/10.1016\/j.rbre.2014.02.006.","DOI":"10.1016\/j.rbre.2014.02.006"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_006","doi-asserted-by":"crossref","unstructured":"Ling, M, Murali, M. Antinuclear antibody tests. Clin Lab Med 2019;39:513\u201324. https:\/\/doi.org\/10.1016\/j.cll.2019.07.001.","DOI":"10.1016\/j.cll.2019.07.001"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_007","doi-asserted-by":"crossref","unstructured":"Meroni, PL, Schur, PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:1420\u20132. https:\/\/doi.org\/10.1136\/ard.2009.127100.","DOI":"10.1136\/ard.2009.127100"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_008","doi-asserted-by":"crossref","unstructured":"Agmon-Levin, N, Damoiseaux, J, Kallenberg, C, Sack, U, Witte, T, Herold, M, et al.. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17\u201323. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203863.","DOI":"10.1136\/annrheumdis-2013-203863"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_009","doi-asserted-by":"crossref","unstructured":"Aringer, M, Costenbader, K, Daikh, D, Brinks, R, Mosca, M, Ramsey-Goldman, R, et al.. European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400\u201312. https:\/\/doi.org\/10.1002\/art.40930.","DOI":"10.1002\/art.40930"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_010","doi-asserted-by":"crossref","unstructured":"Orme, ME, Andalucia, C, Sjolander, S, Bossuyt, X. A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases. Clin Chem Lab Med 2021;59:547\u201361. https:\/\/doi.org\/10.1515\/cclm-2020-0094.","DOI":"10.1515\/cclm-2020-0094"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_011","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Fieuws, S. Detection of antinuclear antibodies: added value of solid phase assay? Ann Rheum Dis 2014;73:e10. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204793.","DOI":"10.1136\/annrheumdis-2013-204793"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_012","doi-asserted-by":"crossref","unstructured":"Orme, ME, Andalucia, C, Sjolander, S, Bossuyt, X. A comparison of a fluorescence enzyme immunoassay vs. indirect immunofluorescence for initial screening of connective tissue diseases: systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol 2018;32:521\u201334. https:\/\/doi.org\/10.1016\/j.berh.2019.03.005.","DOI":"10.1016\/j.berh.2019.03.005"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_013","doi-asserted-by":"crossref","unstructured":"Bizzaro, N. Can solid-phase assays replace immunofluorescence for ANA screening? Ann Rheum Dis 2020;79:e32. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214805.","DOI":"10.1136\/annrheumdis-2018-214805"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_014","doi-asserted-by":"crossref","unstructured":"Willems, P, De Langhe, E, Claessens, J, Westhovens, R, Van Hoeyveld, E, Poesen, K, et al.. Screening for connective tissue disease-associated antibodies by automated immunoassay. Clin Chem Lab Med 2018;56:909\u201318. https:\/\/doi.org\/10.1515\/cclm-2017-0905.","DOI":"10.1515\/cclm-2017-0905"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_015","doi-asserted-by":"crossref","unstructured":"Op De Beeck, K, Vermeersch, P, Verschueren, P, Westhovens, R, Marien, G, Blockmans, D, et al.. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011;10:801\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2011.06.005.","DOI":"10.1016\/j.autrev.2011.06.005"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_016","doi-asserted-by":"crossref","unstructured":"Claessens, J, Belmondo, T, De Langhe, E, Westhovens, R, Poesen, K, Hue, S, et al.. Solid phase assays vs. automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmun Rev 2018;17:533\u201340. https:\/\/doi.org\/10.1016\/j.autrev.2018.03.002.","DOI":"10.1016\/j.autrev.2018.03.002"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_017","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Claessens, J, De Langhe, E, Belmondo, T, Westhovens, R, Hue, S, et al.. Antinuclear antibodies by indirect immunofluorescence and solid phase assays. Ann Rheum Dis 2020;79:e65. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215443.","DOI":"10.1136\/annrheumdis-2019-215443"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_018","doi-asserted-by":"crossref","unstructured":"Bizzaro, N, Brusca, I, Previtali, G, Alessio, MG, Daves, M, Platzgummer, S, et al.. The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases. Autoimmun Rev 2018;17:541\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.007.","DOI":"10.1016\/j.autrev.2017.12.007"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_019","doi-asserted-by":"crossref","unstructured":"Ravelli, A, Felici, E, Magni-Manzoni, S, Pistorio, A, Novarini, C, Bozzola, E, et al.. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005;52:826\u201332. https:\/\/doi.org\/10.1002\/art.20945.","DOI":"10.1002\/art.20945"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_020","doi-asserted-by":"crossref","unstructured":"Ravelli, A, Varnier, GC, Oliveira, S, Castell, E, Arguedas, O, Magnani, A, et al.. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:267\u201375. https:\/\/doi.org\/10.1002\/art.30076.","DOI":"10.1002\/art.30076"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_021","doi-asserted-by":"crossref","unstructured":"Rypdal, V, Glerup, M, Songstad, NT, Bertelsen, G, Christoffersen, T, Arnstad, ED, et al.. Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study. Ophthalmology 2021;128:598\u2013608. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.024.","DOI":"10.1016\/j.ophtha.2020.08.024"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_022","doi-asserted-by":"crossref","unstructured":"Nordal, E, Rypdal, V, Christoffersen, T, Aalto, K, Berntson, L, Fasth, A, et al.. Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study. Pediatr Rheumatol Online J 2017;15:66. https:\/\/doi.org\/10.1186\/s12969-017-0195-8.","DOI":"10.1186\/s12969-017-0195-8"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_023","doi-asserted-by":"crossref","unstructured":"Saurenmann, RK, Levin, AV, Feldman, BM, Laxer, RM, Schneider, R, Silverman, ED. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1824\u20138. https:\/\/doi.org\/10.1002\/art.27416.","DOI":"10.1002\/art.27416"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_024","doi-asserted-by":"crossref","unstructured":"Nordal, EB, Songstad, NT, Berntson, L, Moen, T, Straume, B, Rygg, M. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol 2009;36:1737\u201343. https:\/\/doi.org\/10.3899\/jrheum.081318.","DOI":"10.3899\/jrheum.081318"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_025","doi-asserted-by":"crossref","unstructured":"Storwick, JA, Brett, A, Buhler, K, Chin, A, Schmeling, H, Johnson, N, et al.. Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: a systematic review and meta-analysis. Autoimmun Rev 2022;21:103086. https:\/\/doi.org\/10.1016\/j.autrev.2022.103086.","DOI":"10.1016\/j.autrev.2022.103086"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_026","doi-asserted-by":"crossref","unstructured":"Alvarez, F, Berg, PA, Bianchi, FB, Bianchi, L, Burroughs, AK, Cancado, EL, et al.. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929\u201338. https:\/\/doi.org\/10.1016\/s0168-8278(99)80297-9.","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_027","doi-asserted-by":"crossref","unstructured":"Hennes, EM, Zeniya, M, Czaja, AJ, Pares, A, Dalekos, GN, Krawitt, EL, et al.. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169\u201376. https:\/\/doi.org\/10.1002\/hep.22322.","DOI":"10.1002\/hep.22322"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_028","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63:971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_029","doi-asserted-by":"crossref","unstructured":"Mieli-Vergani, G, Vergani, D, Baumann, U, Czubkowski, P, Debray, D, Dezsofi, A, et al.. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2018;66:345\u201360. https:\/\/doi.org\/10.1097\/mpg.0000000000001801.","DOI":"10.1097\/MPG.0000000000001801"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_030","doi-asserted-by":"crossref","unstructured":"Porcelli, B, Terzuoli, L, Bacarelli, MR, Cinci, F, Bizzaro, N. How reliable is the detection of anti-mitochondrial antibodies on murine triple-tissue? Clin Chem Lab Med 2020;58:e142\u20133. https:\/\/doi.org\/10.1515\/cclm-2019-1210.","DOI":"10.1515\/cclm-2019-1210"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_031","doi-asserted-by":"crossref","unstructured":"Florin, L, Rubben, K, Vanhaecke, A, Devreese, K, De Keyser, F, Smith, V, et al.. Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients. Clin Chem Lab Med 2020;58:416\u201323. https:\/\/doi.org\/10.1515\/cclm-2019-0655.","DOI":"10.1515\/cclm-2019-0655"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_032","doi-asserted-by":"crossref","unstructured":"Guo, YP, Wang, CG, Liu, X, Huang, YQ, Guo, DL, Jing, XZ, et al.. The prevalence of antinuclear antibodies in the general population of China: a cross-sectional study. Curr Ther Res Clin Exp 2014;76:116\u20139. https:\/\/doi.org\/10.1016\/j.curtheres.2014.06.004.","DOI":"10.1016\/j.curtheres.2014.06.004"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_033","doi-asserted-by":"crossref","unstructured":"Satoh, M, Chan, EK, Ho, LA, Rose, KM, Parks, CG, Cohn, RD, et al.. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319\u201327. https:\/\/doi.org\/10.1002\/art.34380.","DOI":"10.1002\/art.34380"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_034","doi-asserted-by":"crossref","unstructured":"Akmatov, MK, Rober, N, Ahrens, W, Flesch-Janys, D, Fricke, J, Greiser, H, et al.. Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders-findings of a multicenter population-based study. Arthritis Res Ther 2017;19:127. https:\/\/doi.org\/10.1186\/s13075-017-1338-5.","DOI":"10.1186\/s13075-017-1338-5"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_035","doi-asserted-by":"crossref","unstructured":"Mariz, HA, Sato, EI, Barbosa, SH, Rodrigues, SH, Dellavance, A, Andrade, LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191\u2013200. https:\/\/doi.org\/10.1002\/art.30084.","DOI":"10.1002\/art.30084"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_036","doi-asserted-by":"crossref","unstructured":"Wener, MH, Fink, SL, Morishima, C, Chaudhary, A, Hutchinson, K. Anti-nuclear antibody quantitation: calibration and harmonization adjustment via population interrogation. J Appl Lab Med 2022;7:46\u201356. https:\/\/doi.org\/10.1093\/jalm\/jfab142.","DOI":"10.1093\/jalm\/jfab142"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_037","doi-asserted-by":"crossref","unstructured":"Sperotto, F, Cuffaro, G, Brachi, S, Seguso, M, Zulian, F. Prevalence of antinuclear antibodies in schoolchildren during puberty and possible relationship with musculoskeletal pain: a longitudinal study. J Rheumatol 2014;41:1405\u20138. https:\/\/doi.org\/10.3899\/jrheum.130948.","DOI":"10.3899\/jrheum.130948"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_038","doi-asserted-by":"crossref","unstructured":"Hilario, MO, Len, CA, Roja, SC, Terreri, MT, Almeida, G, Andrade, LE. Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr 2004;43:637\u201342. https:\/\/doi.org\/10.1177\/000992280404300709.","DOI":"10.1177\/000992280404300709"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_039","doi-asserted-by":"crossref","unstructured":"Somers, EC, Monrad, SU, Warren, JS, Solano, M, Schnaas, L, Hernandez-Avila, M, et al.. Antinuclear antibody prevalence in a general pediatric cohort from Mexico City: discordance between immunofluorescence and multiplex assays. Clin Epidemiol 2017;9:1\u20138. https:\/\/doi.org\/10.2147\/clep.s121632.","DOI":"10.2147\/CLEP.S121632"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_040","unstructured":"Wananukul, S, Voramethkul, W, Kaewopas, Y, Hanvivatvong, O. Prevalence of positive antinuclear antibodies in healthy children. Asian Pac J Allergy Immunol 2005;23:153\u20137."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_041","doi-asserted-by":"crossref","unstructured":"Arroyave, CM, Giambrone, MJ, Rich, KC, Walaszek, M. The frequency of antinuclear antibody (ANA) in children by use of mouse kidney (MK) and human epithelial cells (HEp-2) as substrates. J Allergy Clin Immunol 1988;82:741\u20134. https:\/\/doi.org\/10.1016\/0091-6749(88)90073-5.","DOI":"10.1016\/0091-6749(88)90073-5"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_042","doi-asserted-by":"crossref","unstructured":"Wichainun, R, Kasitanon, N, Wangkaew, S, Hongsongkiat, S, Sukitawut, W, Louthrenoo, W. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pac J Allergy Immunol 2013;31:292\u20138. https:\/\/doi.org\/10.12932\/ap0272.31.4.2013.","DOI":"10.12932\/AP0272.31.4.2013"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_043","doi-asserted-by":"crossref","unstructured":"Mohammed, ME, Abdelhafiz, K. Autoantibodies in the sera of breast cancer patients: antinuclear and anti-double stranded DNA antibodies as example. J Cancer Res Therapeut 2015;11:341\u20134. https:\/\/doi.org\/10.4103\/0973-1482.157314.","DOI":"10.4103\/0973-1482.157314"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_044","doi-asserted-by":"crossref","unstructured":"Agustinelli, RA, Rodrigues, SH, Mariz, HA, Prado, MS, Andrade, LEC. Distinctive features of positive anti-cell antibody tests (indirect immunofluorescence on HEp-2 cells) in patients with non-autoimmune diseases. Lupus 2019;28:629\u201334. https:\/\/doi.org\/10.1177\/0961203319838348.","DOI":"10.1177\/0961203319838348"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_045","doi-asserted-by":"crossref","unstructured":"Chan, EKL, von M\u00fchlen, CA, Fritzler, MJ, Damoiseaux, J, Infantino, M, Klotz, W, et al.., ICAP Committee. The International Consensus on ANA Patterns (ICAP) in 2021-the 6th workshop and current perspectives. J Appl Lab Med 2022;7:322\u201330. https:\/\/doi.org\/10.1093\/jalm\/jfab140.","DOI":"10.1093\/jalm\/jfac013"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_046","doi-asserted-by":"crossref","unstructured":"von Muhlen, CA, Garcia-De La Torre, I, Infantino, M, Damoiseaux, J, Andrade, LEC, Carballo, OG, et al.. How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. Immunol Res 2021;69:594\u2013608. https:\/\/doi.org\/10.1007\/s12026-021-09233-0.","DOI":"10.1007\/s12026-021-09233-0"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_047","unstructured":"Clinical and Laboratory Standards Institute. CLSI I\/LA2-A. Quality assurance for the indirect immunofluorescence test for autoantibodies to nuclear antigen (IF-ANA). Approved guideline. USA: CLSI; 1996."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_048","unstructured":"Clinical and Laboratory Standards Institute. CLSI I\/LA02-A2. Quality assurance of laboratory tests for autoantibodies to nuclear antigens: (1) indirect fluorescence assay for microscopy and (2) microtiter enzyme immunoassay methods. Wayne, PA, USA: CLSI; 2006."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_049","unstructured":"Damoiseaux, J, Agmon-Levin, N, Van Blerk, M, Chopyak, V, Eriksson, C, Heijnen, I, et al.. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clin Exp Rheumatol 2014;32:539\u201346."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_050","unstructured":"Goodwin, JS, Searles, RP, Tung, KS. Immunological responses of healthy elderly population. Clin Exp Immunol 1982;48:403\u201310."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_051","doi-asserted-by":"crossref","unstructured":"Arnaud, L, Fagot, JP, Mathian, A, Paita, M, Fagot-Campagna, A, Amoura, Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev 2014;13:1082\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.034.","DOI":"10.1016\/j.autrev.2014.08.034"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_052","doi-asserted-by":"crossref","unstructured":"Svensson, J, Arkema, EV, Lundberg, IE, Holmqvist, M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology 2017;56:802\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/kew503.","DOI":"10.1093\/rheumatology\/kew503"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_053","doi-asserted-by":"crossref","unstructured":"Royle, JG, Lanyon, PC, Grainge, MJ, Abhishek, A, Pearce, FA. The incidence, prevalence, and survival of systemic sclerosis in the UK clinical practice research datalink. Clin Rheumatol 2018;37:2103\u201311. https:\/\/doi.org\/10.1007\/s10067-018-4182-3.","DOI":"10.1007\/s10067-018-4182-3"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_054","doi-asserted-by":"crossref","unstructured":"Thierry, S, Fautrel, B, Lemelle, I, Guillemin, F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014;81:112\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003.","DOI":"10.1016\/j.jbspin.2013.09.003"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_055","doi-asserted-by":"crossref","unstructured":"Willems, P, De Langhe, E, Westhovens, R, Vanderschueren, S, Blockmans, D, Bossuyt, X. Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities. Ann Rheum Dis 2019;78:e76. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213821.","DOI":"10.1136\/annrheumdis-2018-213821"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_056","doi-asserted-by":"crossref","unstructured":"Bossuyt, X., Fierz, W., & Meroni, P. L. (2021). Correspondence on \u201cEuropean League Against Rheumatism (EULAR)\/American College of Rheumatology (ACR) SLE classification criteria item performance\u201d by Aringer et al. Annals of the rheumatic diseases, annrheumdis-2021-221288. Advance online publication. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221288","DOI":"10.1136\/annrheumdis-2021-221288"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_057","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Claessens, J, Belmondo, T, De Langhe, E, Westhovens, R, Poesen, K, et al.. Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmun Rev 2019;18:102386. https:\/\/doi.org\/10.1016\/j.autrev.2019.102386.","DOI":"10.1016\/j.autrev.2019.102386"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_058","doi-asserted-by":"crossref","unstructured":"Vulsteke, JB, Van Hoovels, L, Willems, P, Vander Cruyssen, B, Vanderschueren, S, Westhovens, R, et al.. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis 2019;80:e128. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216245.","DOI":"10.1136\/annrheumdis-2019-216245"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_059","doi-asserted-by":"crossref","unstructured":"Cheng, CF, Lan, TY, Shih, MC, Li, KJ. Monospecific anti-DFS70 antibodies are moderately helpful in excluding ANA-associated rheumatic disease in patients presenting with a dense fine speckled pattern\u00a0\u2013 a systematic review and meta-analysis of diagnostic test accuracy. Autoimmun Rev 2020;19:102637. https:\/\/doi.org\/10.1016\/j.autrev.2020.102637.","DOI":"10.1016\/j.autrev.2020.102637"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_060","doi-asserted-by":"crossref","unstructured":"Vermeersch, P, Bossuyt, X. Comparative analysis of different approaches to report diagnostic accuracy. Arch Intern Med 2010;170:734\u20135. https:\/\/doi.org\/10.1001\/archinternmed.2010.84.","DOI":"10.1001\/archinternmed.2010.84"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_061","doi-asserted-by":"crossref","unstructured":"Bossuyt, X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009;8:543\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2009.01.013.","DOI":"10.1016\/j.autrev.2009.01.013"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_062","doi-asserted-by":"crossref","unstructured":"Malleson, PN, Sailer, M, Mackinnon, MJ. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997;77:299\u2013304. https:\/\/doi.org\/10.1136\/adc.77.4.299.","DOI":"10.1136\/adc.77.4.299"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_063","doi-asserted-by":"crossref","unstructured":"McGhee, JL, Kickingbird, LM, Jarvis, JN. Clinical utility of antinuclear antibody tests in children. BMC Pediatr 2004;4:13. https:\/\/doi.org\/10.1186\/1471-2431-4-13.","DOI":"10.1186\/1471-2431-4-13"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_064","doi-asserted-by":"crossref","unstructured":"Chan, EK, Damoiseaux, J, Carballo, OG, Conrad, K, de Melo Cruvinel, W, Francescantonio, PL, et al.. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015. Front Immunol 2015;6:412. https:\/\/doi.org\/10.3389\/fimmu.2015.00412.","DOI":"10.3389\/fimmu.2015.00412"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_065","doi-asserted-by":"crossref","unstructured":"Damoiseaux, J, Andrade, LEC, Carballo, OG, Conrad, K, Francescantonio, PLC, Fritzler, MJ, et al.. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 2019;78:879\u201389. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214436.","DOI":"10.1136\/annrheumdis-2018-214436"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_066","doi-asserted-by":"crossref","unstructured":"Cruvinel, WM, Andrade, LEC, von Muhlen, CA, Dellavance, A, Ximenes, AC, Bichara, CD, et al.. V Brazilian consensus guidelines for detection of anti-cell autoantibodies on HEp-2 cells. Adv Rheumatol 2019;59:28. https:\/\/doi.org\/10.1186\/s42358-019-0069-5.","DOI":"10.1186\/s42358-019-0069-5"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_067","unstructured":"van Beek, AA, Schreurs, MWJ, Otten, HG, Bergkamp, FJM, Damoiseaux, JGMC. The updated Dutch guideline for laboratory diagnostics of ANA-associated auto-immune diseases. Paper Nederland Van Beek et\u00a0al. Nederlands Tijdschr Allerg Klin Immunol 2021;2:58\u201364."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_068","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Broeders, S, Chan, EKL, Andrade, L, de Melo Cruvinel, W, Damoiseaux, J, et al.. Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. Auto Immun Highlights 2020;11:17. https:\/\/doi.org\/10.1186\/s13317-020-00139-9.","DOI":"10.1186\/s13317-020-00139-9"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_069","doi-asserted-by":"crossref","unstructured":"Tebo, AE, Schmidt, RL, Kadkhoda, K, Peterson, LK, Chan, EKL, Fritzler, MJ, et al.. The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation. Auto Immun Highlights 2021;12:4. https:\/\/doi.org\/10.1186\/s13317-020-00146-w.","DOI":"10.1186\/s13317-020-00146-w"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_070","doi-asserted-by":"crossref","unstructured":"Vermeersch, P, Van den Bergh, K, Blockmans, D, Westhovens, R, Bossuyt, X. Anti-Golgi autoantibodies are not clinically associated with systemic autoimmune diseases. Ann Rheum Dis 2011;70:234\u20135. https:\/\/doi.org\/10.1136\/ard.2009.126391.","DOI":"10.1136\/ard.2009.126391"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_071","doi-asserted-by":"crossref","unstructured":"Vermeersch, P, Bossuyt, X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013;12:998\u20131003. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.014.","DOI":"10.1016\/j.autrev.2013.03.014"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_072","doi-asserted-by":"crossref","unstructured":"Peterson, LK, Tebo, AE, Wener, MH, Copple, SS, Fritzler, MJ. Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists. Clin Chem Lab Med 2020;58:1489\u201397. https:\/\/doi.org\/10.1515\/cclm-2019-1262.","DOI":"10.1515\/cclm-2019-1262"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_073","doi-asserted-by":"crossref","unstructured":"Irure-Ventura, J, Rodriguez, C, Vergara-Prieto, E, Vargas, ML, Quirant, B, Jurado, A, et al.. Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: a Spanish multicentre study. Rheumatology 2021;60:3904\u201312.","DOI":"10.1093\/rheumatology\/keaa831"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_074","doi-asserted-by":"crossref","unstructured":"Vermeersch, P, De Beeck, KO, Lauwerys, BR, Van den Bergh, K, Develter, M, Marien, G, et al.. Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus. Ann Rheum Dis 2009;68:1791\u20133. https:\/\/doi.org\/10.1136\/ard.2008.104190.","DOI":"10.1136\/ard.2008.104190"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_075","doi-asserted-by":"crossref","unstructured":"Dellavance, A, Cruvinel, W, Francescantonio, P, Mangueira, C, Drugowick, I, Rodrigues, S, et al.. Variability in the recognition of distinctive immunofluorescence patterns in different brands of HEp-2 cell slides. J Bras Patol Med Lab 2013;49:182\u201390. https:\/\/doi.org\/10.1590\/s1676-24442013000300005.","DOI":"10.1590\/S1676-24442013000300005"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_076","doi-asserted-by":"crossref","unstructured":"Dellavance, A, Can\u00e7ado, EL, Abrantes-Lemos, CP, Harriz, M, Marvulle, V, Andrade, LE. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2012;7:775\u201384. https:\/\/doi.org\/10.1007\/s12072-012-9413-0.","DOI":"10.1007\/s12072-012-9413-0"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_077","doi-asserted-by":"crossref","unstructured":"Bizzaro, N, Tonutti, E, Villalta, D. Recognizing the dense fine speckled\/lens epithelium-derived growth factor\/p75 pattern on HEp-2 cells: not an easy task! Comment on the article by Mariz et\u00a0al. Arthritis Rheum 2011;63:4036\u20137. https:\/\/doi.org\/10.1002\/art.30621.","DOI":"10.1002\/art.30621"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_078","doi-asserted-by":"crossref","unstructured":"Bentow, C, Fritzler, MJ, Mummert, E, Mahler, M. Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 2016;7:8. https:\/\/doi.org\/10.1007\/s13317-016-0081-2.","DOI":"10.1007\/s13317-016-0081-2"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_079","doi-asserted-by":"crossref","unstructured":"Dellavance, A, Baldo, DC, Zheng, B, Mora, RA, Fritzler, MJ, Hiepe, F, et al.. Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera. Clin Chem Lab Med 2019;57:1754\u201363. https:\/\/doi.org\/10.1515\/cclm-2019-0087.","DOI":"10.1515\/cclm-2019-0087"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_080","doi-asserted-by":"crossref","unstructured":"Bonroy, C, Schouwers, S, Berth, M, Stubbe, M, Piette, Y, Hoffman, I, et al.. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med 2018;56:1090\u20139. https:\/\/doi.org\/10.1515\/cclm-2017-0541.","DOI":"10.1515\/cclm-2017-0541"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_081","doi-asserted-by":"crossref","unstructured":"Mahler, M, Parker, T, Peebles, CL, Andrade, LE, Swart, A, Carbone, Y, et al.. Anti-DFS70\/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012;39:2104\u201310. https:\/\/doi.org\/10.3899\/jrheum.120598.","DOI":"10.3899\/jrheum.120598"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_082","doi-asserted-by":"crossref","unstructured":"Albesa, R, Sachs, U, Infantino, M, Manfredi, M, Benucci, M, Baus, Y, et al.. Increased prevalence of anti-DFS70 antibodies in young females: experience from a large international multi-center study on blood donors. Clin Chem Lab Med 2019;57:999\u20131005. https:\/\/doi.org\/10.1515\/cclm-2018-1233.","DOI":"10.1515\/cclm-2018-1233"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_083","doi-asserted-by":"crossref","unstructured":"Choi, MY, Clarke, E, St Pierre, Y, Hanly, JG, Urowitz, MB, Romero-Diaz, J, et al.. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 2017;26:1051\u20139. https:\/\/doi.org\/10.1177\/0961203317692437.","DOI":"10.1177\/0961203317692437"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_084","doi-asserted-by":"crossref","unstructured":"Andrade, LEC, Klotz, W, Herold, M, Conrad, K, Ronnelid, J, Fritzler, MJ, et al.. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 2018;56:1783\u20138. https:\/\/doi.org\/10.1515\/cclm-2018-0188.","DOI":"10.1515\/cclm-2018-0188"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_085","doi-asserted-by":"crossref","unstructured":"Lee, LA. Cutaneous lupus in infancy and childhood. Lupus 2010;19:1112\u20137. https:\/\/doi.org\/10.1177\/0961203310370347.","DOI":"10.1177\/0961203310370347"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_086","doi-asserted-by":"crossref","unstructured":"Damoiseaux, J, Chan, EK. Response to: \u2018the utility of the HEp-2000 antinuclear antibody substrate\u2019 by Lee et\u00a0al. Ann Rheum Dis 2020;79:e68. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215610.","DOI":"10.1136\/annrheumdis-2019-215610"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_087","doi-asserted-by":"crossref","unstructured":"Lee, AYS, Beroukas, D, Roberts-Thomson, PJ. Utility of the HEp-2000 antinuclear antibody substrate. Ann Rheum Dis 2020;79:e67. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215519.","DOI":"10.1136\/annrheumdis-2019-215519"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_088","doi-asserted-by":"crossref","unstructured":"Fritzler, MJ, Hanson, C, Miller, J, Eystathioy, T. Specificity of autoantibodies to SS-A\/Ro on a transfected and overexpressed human 60\u00a0kDa Ro autoantigen substrate. J Clin Lab Anal 2002;16:103\u20138. https:\/\/doi.org\/10.1002\/jcla.10026.","DOI":"10.1002\/jcla.10026"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_089","doi-asserted-by":"crossref","unstructured":"Keech, CL, McCluskey, J, Gordon, TP. Transfection and overexpression of the human 60-kDa Ro\/SS-A autoantigen in HEp-2 cells. Clin Immunol Immunopathol 1994;73:146\u201351. https:\/\/doi.org\/10.1006\/clin.1994.1181.","DOI":"10.1006\/clin.1994.1181"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_090","doi-asserted-by":"crossref","unstructured":"Peene, I, Van Ael, W, Vandenbossche, M, Vervaet, T, Veys, E, De Keyser, F. Sensitivity of the HEp-2000 substrate for the detection of anti-SSA\/Ro60 antibodies. Clin Rheumatol 2000;19:291\u20135. https:\/\/doi.org\/10.1007\/s100670070048.","DOI":"10.1007\/s100670070048"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_091","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Meurs, L, Mewis, A, Marien, G, Blanckaert, N. Screening for autoantibodies to SS-A\/RO by indirect immunofluorescence using HEp-2000 cells. Ann Clin Biochem 2000;37:216\u20139. https:\/\/doi.org\/10.1258\/0004563001899032.","DOI":"10.1258\/0004563001899032"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_092","doi-asserted-by":"crossref","unstructured":"Pollock, W, Toh, BH. Routine immunofluorescence detection of Ro\/SS-A autoantibody using HEp-2 cells transfected with human 60\u00a0kDa Ro\/SS-A. J Clin Pathol 1999;52:684\u20137. https:\/\/doi.org\/10.1136\/jcp.52.9.684.","DOI":"10.1136\/jcp.52.9.684"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_093","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Frans, J, Hendrickx, A, Godefridis, G, Westhovens, R, Marien, G. Detection of anti-SSA antibodies by indirect immunofluorescence. Clin Chem 2004;50:2361\u20139. https:\/\/doi.org\/10.1373\/clinchem.2004.035964.","DOI":"10.1373\/clinchem.2004.035964"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_094","doi-asserted-by":"crossref","unstructured":"Hoffman, IE, Peene, I, Veys, EM, De Keyser, F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002;48:2171\u20136. https:\/\/doi.org\/10.1093\/clinchem\/48.12.2171.","DOI":"10.1093\/clinchem\/48.12.2171"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_095","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Luyckx, A. Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples. Clin Chem 2005;51:2426\u20137. https:\/\/doi.org\/10.1373\/clinchem.2005.058552.","DOI":"10.1373\/clinchem.2005.058552"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_096","unstructured":"Kidd, K, Cusi, K, Mueller, R, Goodner, M, Boyes, B, Hoy, E. Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab 2005;51:517\u201321."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_097","doi-asserted-by":"crossref","unstructured":"Pisetsky, DS, Thompson, DK, Wajdula, J, Diehl, A, Sridharan, S. Variability in antinuclear antibody testing to assess patient eligibility for clinical trials of novel treatments for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1534\u20138. https:\/\/doi.org\/10.1002\/art.40910.","DOI":"10.1002\/art.40910"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_098","doi-asserted-by":"crossref","unstructured":"R\u00f6ber, N, Dellavance, A, Ing\u00e9nito, F, Reimer, ML, Carballo, OG, Conrad, K, et al.. Strong association of the myriad discrete speckled nuclear pattern with anti-SS-A\/Ro60 antibodies: consensus experience of four international expert centers. Front Immunol 2021;12:730102. https:\/\/doi.org\/10.3389\/fimmu.2021.730102.","DOI":"10.3389\/fimmu.2021.730102"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_099","unstructured":"de Vlam, K, De Keyser, F, Verbruggen, G, Vandenbossche, M, Vanneuville, B, D\u2019Haese, D, et al.. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 1993;11:393\u20137."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_100","unstructured":"Arcavi, M, Dadone, J. Antinuclear antibodies, patterns and characteristics obtained by immunofluorescence. The importance of the IgA, IgM and IgG isotypes. Medicina 2009;69:502\u20136."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_101","doi-asserted-by":"crossref","unstructured":"Humbel, R. Detection of antinuclear antibodies by immunofluorescence. In: Van Venrooij, W, Maini, R, editors. Manual of biological markers of disease. Norwell, MA: Klevier Academic Publishers; 1993.","DOI":"10.1007\/978-94-011-5444-4_2"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_102","doi-asserted-by":"crossref","unstructured":"Kavanaugh, A, Tomar, R, Reveille, J, Solomon, DH, Homburger, HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000;124:71\u201381. https:\/\/doi.org\/10.5858\/2000-124-0071-gfcuot.","DOI":"10.5858\/2000-124-0071-GFCUOT"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_103","doi-asserted-by":"crossref","unstructured":"Infantino, M, Meacci, F, Grossi, V, Manfredi, M, Benucci, M, Merone, M, et al.. The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test. Immunol Res 2017;65:345\u201354. https:\/\/doi.org\/10.1007\/s12026-016-8845-3.","DOI":"10.1007\/s12026-016-8845-3"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_104","doi-asserted-by":"crossref","unstructured":"Harmon, CE. Antinuclear antibodies in autoimmune disease. Significance and pathogenicity. Med Clin North Am 1985;69:547\u201363.","DOI":"10.1016\/S0025-7125(16)31032-X"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_105","doi-asserted-by":"crossref","unstructured":"De Rycke, L, Kruithof, E, Van Damme, N, Hoffman, IE, Van den Bossche, N, Van den Bosch, F, et al.. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015\u201323. https:\/\/doi.org\/10.1002\/art.10876.","DOI":"10.1002\/art.10876"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_106","doi-asserted-by":"crossref","unstructured":"Vermeire, S, Noman, M, Van Assche, G, Baert, F, Van Steen, K, Esters, N, et al.. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study. Gastroenterology 2003;125:32\u20139. https:\/\/doi.org\/10.1016\/s0016-5085(03)00701-7.","DOI":"10.1016\/S0016-5085(03)00701-7"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_107","doi-asserted-by":"crossref","unstructured":"Bertin, D, Jourde-Chiche, N, Bongrand, P, Bardin, N. Original approach for automated quantification of antinuclear autoantibodies by indirect immunofluorescence. Clin Dev Immunol 2013;2013:182172. https:\/\/doi.org\/10.1155\/2013\/182172.","DOI":"10.1155\/2013\/182172"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_108","doi-asserted-by":"crossref","unstructured":"Bertin, D, Mouhajir, Y, Bongrand, P, Bardin, N. ICARE improves antinuclear antibody detection by overcoming the barriers preventing accreditation. Clin Chim Acta 2016;454:57\u201361. https:\/\/doi.org\/10.1016\/j.cca.2015.12.034.","DOI":"10.1016\/j.cca.2015.12.034"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_109","doi-asserted-by":"crossref","unstructured":"Bonroy, C, Verfaillie, C, Smith, V, Persijn, L, De Witte, E, De Keyser, F, et al.. Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med 2013;51:1771\u20139. https:\/\/doi.org\/10.1515\/cclm-2013-0016.","DOI":"10.1515\/cclm-2013-0016"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_110","doi-asserted-by":"crossref","unstructured":"Bizzaro, N, Antico, A, Platzgummer, S, Tonutti, E, Bassetti, D, Pesente, F, et al.. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev 2014;13:292\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.015.","DOI":"10.1016\/j.autrev.2013.10.015"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_111","doi-asserted-by":"crossref","unstructured":"Egerer, K, Roggenbuck, D, Hiemann, R, Weyer, MG, Buttner, T, Radau, B, et al.. Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther 2010;12:R40. https:\/\/doi.org\/10.1186\/ar2949.","DOI":"10.1186\/ar2949"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_112","doi-asserted-by":"crossref","unstructured":"Bentow, C, Lakos, G, Rosenblum, R, Bryant, C, Seaman, A, Mahler, M. Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA flash CTD screen plus. Immunol Res 2015;61:110\u20136. https:\/\/doi.org\/10.1007\/s12026-014-8601-5.","DOI":"10.1007\/s12026-014-8601-5"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_113","doi-asserted-by":"crossref","unstructured":"Yoo, IY, Oh, JW, Cha, HS, Koh, EM, Kang, ES. Performance of an automated fluorescence antinuclear antibody image analyzer. Ann Lab Med 2017;37:240\u20137. https:\/\/doi.org\/10.3343\/alm.2017.37.3.240.","DOI":"10.3343\/alm.2017.37.3.240"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_114","doi-asserted-by":"crossref","unstructured":"Melegari, A, Bonaguri, C, Russo, A, Luisita, B, Trenti, T, Lippi, G. A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev 2012;11:713\u20136. https:\/\/doi.org\/10.1016\/j.autrev.2011.12.010.","DOI":"10.1016\/j.autrev.2011.12.010"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_115","doi-asserted-by":"crossref","unstructured":"Voigt, J, Krause, C, Rohwader, E, Saschenbrecker, S, Hahn, M, Danckwardt, M, et al.. Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells. Clin Dev Immunol 2012;2012:651058. https:\/\/doi.org\/10.1155\/2012\/651058.","DOI":"10.1155\/2012\/651058"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_116","doi-asserted-by":"crossref","unstructured":"Loock, CD, Egerer, K, Feist, E, Burmester, GR. Automated evaluation of ANA under real-life conditions. RMD Open 2017;3:e000409. https:\/\/doi.org\/10.1136\/rmdopen-2016-000409.","DOI":"10.1136\/rmdopen-2016-000409"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_117","doi-asserted-by":"crossref","unstructured":"Lutteri, L, Dierge, L, Pesser, M, Watrin, P, Cavalier, E. A paperless autoimmunity laboratory: myth or reality? Ann Biol Clin 2016;74:477\u201389. https:\/\/doi.org\/10.1684\/abc.2016.1164.","DOI":"10.1684\/abc.2016.1164"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_118","unstructured":"Hayashi, N, Saegusa, J, Uto, K, Oyabu, C, Saito, T, Sato, I, et al.. Evaluation of a computer-aided microscope system and its anti-nuclear antibody test kit for indirect immunofluorescence assay (English abstract). Rinsho Byori Japanese J Clin Pathol 2016;64:142\u201351."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_119","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Cooreman, S, De Baere, H, Verschueren, P, Westhovens, R, Blockmans, D, et al.. Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clin Chim Acta 2013;415:101\u20136. https:\/\/doi.org\/10.1016\/j.cca.2012.09.021.","DOI":"10.1016\/j.cca.2012.09.021"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_120","doi-asserted-by":"crossref","unstructured":"Copple, SS, Jaskowski, TD, Giles, R, Hill, HR. Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy. J Immunol Res 2014;2014:149316. https:\/\/doi.org\/10.1155\/2014\/149316.","DOI":"10.1155\/2014\/149316"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_121","doi-asserted-by":"crossref","unstructured":"Zheng, B, Li, E, Zhu, H, Lu, J, Shi, X, Zhang, J, et al.. Automated antinuclear immunofluorescence antibody analysis is a reliable approach in routine clinical laboratories. Clin Chem Lab Med 2017;55:1922\u201330. https:\/\/doi.org\/10.1515\/cclm-2017-0050.","DOI":"10.1515\/cclm-2017-0050"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_122","doi-asserted-by":"crossref","unstructured":"Schouwers, S, Bonnet, M, Verschueren, P, Westhovens, R, Blockmans, D, Marien, G, et al.. Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. Clin Chem Lab Med 2014;52:547\u201351. https:\/\/doi.org\/10.1515\/cclm-2013-0610.","DOI":"10.1515\/cclm-2013-0610"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_123","doi-asserted-by":"crossref","unstructured":"Kivity, S, Gilburd, B, Agmon-Levin, N, Carrasco, MG, Tzafrir, Y, Sofer, Y, et al.. A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol 2012;31:503\u20139. https:\/\/doi.org\/10.1007\/s10067-011-1884-1.","DOI":"10.1007\/s10067-011-1884-1"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_124","doi-asserted-by":"crossref","unstructured":"Kim, J, Lee, W, Kim, GT, Kim, HS, Ock, S, Kim, IS, et al.. Diagnostic utility of automated indirect immunofluorescence compared to manual indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: a systematic review and meta-analysis. Semin Arthritis Rheum2019;48:728\u201335. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.015.","DOI":"10.1016\/j.semarthrit.2018.03.015"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_125","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Schouwers, S, Van den Bremt, S, Bogaert, L, Vandeputte, N, Vercammen, M, et al.. Analytical performance of the single well titer function of NOVA View\u00ae: good enough to omit ANA IIF titer analysis? Clin Chem Lab Med 2018;56:258\u201361. https:\/\/doi.org\/10.1515\/cclm-2018-0338.","DOI":"10.1515\/cclm-2018-0338"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_126","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Schouwers, S, Van den Bremt, S, Bossuyt, X. Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis. Ann Rheum Dis 2019;78:e48. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213543.","DOI":"10.1136\/annrheumdis-2018-213543"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_127","doi-asserted-by":"crossref","unstructured":"Roggenbuck, D, Hiemann, R, Schierack, P, Reinhold, D, Conrad, K. Digital immunofluorescence enables automated detection of antinuclear antibody endpoint titers avoiding serial dilution. Clin Chem Lab Med 2014;52:e9\u201311. https:\/\/doi.org\/10.1515\/cclm-2013-0543.","DOI":"10.1515\/cclm-2013-0543"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_128","doi-asserted-by":"crossref","unstructured":"Oyaert, M, Bossuyt, X, Ravelingien, I, Van Hoovels, L. Added value of indirect immunofluorescence intensity of automated antinuclear antibody testing in a secondary hospital setting. Clin Chem Lab Med 2016;54:e63\u20136. https:\/\/doi.org\/10.1515\/cclm-2015-0887.","DOI":"10.1515\/cclm-2015-0887"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_129","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Bossuyt, X, Manfredi, M, Grossi, V, Benucci, M, Van Den Bremt, S, et al.. Integrating quality assurance in autoimmunity: the changing face of the automated ANA IIF test. Clin Chem Lab Med 2021;59:1247\u201355. https:\/\/doi.org\/10.1515\/cclm-2020-1669.","DOI":"10.1515\/cclm-2020-1669"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_130","doi-asserted-by":"crossref","unstructured":"Bogaert, L, Van den Bremt, S, Schouwers, S, Bossuyt, X, Van Hoovels, L. Harmonizing by reducing inter-run variability: performance evaluation of a quality assurance program for antinuclear antibody detection by indirect immunofluorescence. Clin Chem Lab Med 2019;57:990\u20138. https:\/\/doi.org\/10.1515\/cclm-2018-0933.","DOI":"10.1515\/cclm-2018-0933"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_131","doi-asserted-by":"crossref","unstructured":"Van den Bremt, S, Schouwers, S, Van Blerk, M, Van Hoovels, L. ANA IIF automation: moving towards harmonization? Results of a multicenter study. J Immunol Res 2017;2017:6038137. https:\/\/doi.org\/10.1155\/2017\/6038137.","DOI":"10.1155\/2017\/6038137"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_132","doi-asserted-by":"crossref","unstructured":"Maenhout, TM, Bonroy, C, Verfaillie, C, Stove, V, Devreese, K. Automated indirect immunofluorescence microscopy enables the implementation of a quantitative internal quality control system for anti-nuclear antibody (ANA) analysis. Clin Chem Lab Med 2014;52:989\u201398. https:\/\/doi.org\/10.1515\/cclm-2013-0912.","DOI":"10.1515\/cclm-2013-0912"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_133","unstructured":"International Organization for Standardization. EN-ISO 15189: 2012. Medical laboratories\u00a0\u2013 requirements for quality and competence. Geneva, Switzerland: EN-ISO 15189; 2012."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_134","doi-asserted-by":"crossref","unstructured":"Sack, U, Bossuyt, X, Andreeva, H, Antal-Szalmas, P, Bizzaro, N, Bogdanos, D, et al.. Quality and best practice in medical laboratories: specific requests for autoimmunity testing. Auto Immun Highlights 2020;11:12. https:\/\/doi.org\/10.1186\/s13317-020-00134-0.","DOI":"10.1186\/s13317-020-00134-0"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_135","doi-asserted-by":"crossref","unstructured":"Dellavance, A, Andrade, L. Detection of autoantibodies by indirect immunofluorescence cytochemistry on HEp-2 cells. In: Houen, G, editor. Autoantibodies. Methods in Molecular biology, vol 1901. Humana Press, Springer Nature, New York, NY. 2019:19\u201346 pp.","DOI":"10.1007\/978-1-4939-8949-2_3"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_136","doi-asserted-by":"crossref","unstructured":"Higgins, V, Augustin, R, Kulasingam, V, Taher, J. Sample stability of autoantibodies: a tool for laboratory quality initiatives. Clin Biochem 2021;96:43\u20138. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.06.003.","DOI":"10.1016\/j.clinbiochem.2021.06.003"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_137","doi-asserted-by":"crossref","unstructured":"Sack, U, Conrad, K, Csernok, E, Frank, I, Hiepe, F, Krieger, T, et al.. Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 2009;1173:166\u201373. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04735.x.","DOI":"10.1111\/j.1749-6632.2009.04735.x"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_138","doi-asserted-by":"crossref","unstructured":"Westgard, JO, Barry, PL, Hunt, MR, Groth, T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 1981;27:493\u2013501. https:\/\/doi.org\/10.1093\/clinchem\/27.3.493.","DOI":"10.1093\/clinchem\/27.3.493"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_139","unstructured":"Comit\u00e9 Fran\u00e7ais d\u2019Accr\u00e9ditation. Guide technique d\u2019accr\u00e9ditation de v\u00e9rification (port\u00e9e A)\/validation (port\u00e9e B) des methodes en biologie m\u00e9dicale. Document SH GTA 04-R\u00e9vison 01. Paris, France: COFRAC; 2015."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_140","doi-asserted-by":"crossref","unstructured":"Van Blerk, M, Van Campenhout, C, Bossuyt, X, Duchateau, J, Humbel, R, Servais, G, et al.. Current practices in antinuclear antibody testing: results from the Belgian External Quality Assessment Scheme. Clin Chem Lab Med 2009;47:102\u20138. https:\/\/doi.org\/10.1515\/cclm.2009.021.","DOI":"10.1515\/CCLM.2009.021"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_141","doi-asserted-by":"crossref","unstructured":"Rigon, A, Soda, P, Zennaro, D, Iannello, G, Afeltra, A. Indirect immunofluorescence in autoimmune diseases: assessment of digital images for diagnostic purpose. Cytometry B Clin Cytom 2007;72:472\u20137. https:\/\/doi.org\/10.1002\/cyto.b.20356.","DOI":"10.1002\/cyto.b.20356"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_142","doi-asserted-by":"crossref","unstructured":"Pham, BN, Albarede, S, Guyard, A, Burg, E, Maisonneuve, P. Impact of external quality assessment on antinuclear antibody detection performance. Lupus 2005;14:113\u20139. https:\/\/doi.org\/10.1191\/0961203305lu2069oa.","DOI":"10.1191\/0961203305lu2069oa"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_143","doi-asserted-by":"crossref","unstructured":"Copple, SS, Giles, SR, Jaskowski, TD, Gardiner, AE, Wilson, AM, Hill, HR. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am J Clin Pathol 2012;137:825\u201330. https:\/\/doi.org\/10.1309\/ajcpicnfg7uces1s.","DOI":"10.1309\/AJCPICNFG7UCES1S"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_144","doi-asserted-by":"crossref","unstructured":"Silva, MJ, Dellavance, A, Baldo, DC, Rodrigues, SH, Grecco, M, Prado, MS, et al.. Interkit reproducibility of the indirect immunofluorescence assay on HEp-2 cells depends on the immunofluorescence reactivity intensity and pattern. Front Immunol 2022;12:798322. https:\/\/doi.org\/10.3389\/fimmu.2021.798322.","DOI":"10.3389\/fimmu.2021.798322"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_145","unstructured":"CLSI EP26-A. User evaluation of between-reagent lot variation. Approved guideline. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2013."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_146","unstructured":"Thompson, S, Chesher, D. Lot-to-lot variation. Clin Biochem Rev 2018;39:51\u201360."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_147","doi-asserted-by":"crossref","unstructured":"Sandberg, S, Fraser, CG, Horvath, ER, Jansen, R, JonesOosterhuis, GW, Petersen, PH, et al.. Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European federation of clinical chemistry and laboratory medicine. Clin Chem Lab Med 2015;53:833\u20135. https:\/\/doi.org\/10.1515\/cclm-2015-0067.","DOI":"10.1515\/cclm-2015-0067"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_148","doi-asserted-by":"crossref","unstructured":"Damoiseaux, J, Vulsteke, JB, Tseng, CW, Platteel, ACM, Piette, Y, Shovman, O, et al.. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev 2019;18:293\u2013305. https:\/\/doi.org\/10.1016\/j.autrev.2018.10.004.","DOI":"10.1016\/j.autrev.2018.10.004"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_149","unstructured":"World Health Organization. WHO BS\/95.1793. Glossary of terms for biological substances used for texts of the requirements. Geneva Switzerland: World Health Organization Expert Committee on Standardization WHO; 1995."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_150","unstructured":"European parliament, Council of the European Union. Directive 98\/79\/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Off J Eur Communities 1998;331:1\u201337."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_151","unstructured":"Sarewitz, SJ. CAP accreditation requirements for validation of laboratory tests. 2013. Available from: http:\/\/webapps.cap.org\/apps\/docs\/education\/lapaudio\/pdf\/011613.presentation.pdf."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_152","unstructured":"Regulation (EU) 2017\/746 on in vitro diagnostic medical devices and repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU. The European Parliament and the council of the European Union; 2017, 117:176\u2013332 pp."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_153","unstructured":"Joint Committee for Guides in Metrology. JCGM 200:2012: international vocabulary of metrology \u2013 Basic and general concepts and associated terms (VIM). S\u00e8vres cedex: JCGM; 2012."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_154","unstructured":"International Organization for Standardization. ISO 9000:2005 quality management systems\u00a0\u2013 fundamentals and vocabulary. Geneva, Switzerland: ISO; 2005."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_155","unstructured":"CAP \u2013 all common checklist. Northfield: College of American Pathologists; 2017."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_156","unstructured":"Nederlandse Vereniging voor Klinische Chemie en Laboratoriumgeneeskunde. NVKC richtlijn Validatie en Verificatie van onderzoeksprocedures. The Netherlands: NVKC; 2021."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_157","unstructured":"Commissie voor Klinische Biologie. Praktijkrichtlijn voor het opzetten van een kwaliteitshandboek in de erkende laboratoria voor klinische biologie werkzaam binnen het kader van het Erkenningsbesluit. Versie 3. Belgium. Commissie voor Klinische Biologie; 2017."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_158","unstructured":"Clinical and Laboratory Standards Institute. CLSI EP15-A3: user verification of precision and estimation of Bias. Approved guideline, 3rd ed. Wayne, PA, USA: CLSI; 2014."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_159","unstructured":"Clinical and Laboratory Standards Institute. CLSI EP12-A2: user protocol for evaluation of qualitative test performance. Approved guideline, 2nd ed. Wayne, PA, USA: CLSI; 2008."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_160","doi-asserted-by":"crossref","unstructured":"Pum, J. A practical guide to validation and verification of analytical methods in the clinical laboratory. Adv Clin Chem 2019;90:215\u201381. https:\/\/doi.org\/10.1016\/bs.acc.2019.01.006.","DOI":"10.1016\/bs.acc.2019.01.006"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_161","doi-asserted-by":"crossref","unstructured":"Pum, JKW. Evaluation of analytical performance of qualitative and semi-quantitative assays in the clinical laboratory. Clin Chim Acta 2019;497:197\u2013203. https:\/\/doi.org\/10.1016\/j.cca.2019.07.018.","DOI":"10.1016\/j.cca.2019.07.018"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_162","doi-asserted-by":"crossref","unstructured":"Mulder, L, van der Molen, R, Koelman, C, van Leeuwen, E, Roos, A, Damoiseaux, J. Validation conform ISO-15189 of assays in the field of autoimmunity: joint efforts in The Netherlands. Autoimmun Rev 2018;17:513\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2018.03.004.","DOI":"10.1016\/j.autrev.2018.03.004"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_163","unstructured":"Munujos, J. Autoimmune diagnostics by immune-fluorescence: variability and harmonization. Clin Lab Int 2016:38\u201341."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_164","doi-asserted-by":"crossref","unstructured":"Wener, MH, Fink, S, Bashleben, C, Sindelar, S, Linden, MA. Long-term variability in immunofluorescence titer of antibodies to nuclear antigens observed in clinical laboratory proficiency testing surveys. Arch Pathol Lab Med 2021;145:937\u201342. https:\/\/doi.org\/10.5858\/arpa.2020-0419-CP.","DOI":"10.5858\/arpa.2020-0419-CP"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_165","doi-asserted-by":"crossref","unstructured":"McHugh, ML. Interrater reliability: the kappa statistic. Biochem Med 2012;22:276\u201382. https:\/\/doi.org\/10.11613\/bm.2012.031.","DOI":"10.11613\/BM.2012.031"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_166","doi-asserted-by":"crossref","unstructured":"Senant, M, Musset, L, Chyderiotis, G, Guis-Cabanne, L, Damoiseaux, J, Fabien, N, et al.. Precision of autoantibody assays in clinical diagnostic laboratories: what is the reality? Clin Biochem 2020;83:57\u201364. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.05.019.","DOI":"10.1016\/j.clinbiochem.2020.05.019"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_167","unstructured":"Clinical and Laboratory Standards Institute. CLSI EP05-A3: evaluation of precision of quantitative measurement procedures. Approved guideline, 3rd ed. Wayne, PA, USA: CLSI; 2014."},{"key":"2024012310382636134_j_cclm-2023-0209_ref_168","doi-asserted-by":"crossref","unstructured":"Antonelli, G, Padoan, A, Aita, A, Sciacovelli, L, Plebani, M. Verification of examination procedures in clinical laboratory for imprecision, trueness and diagnostic accuracy according to ISO 15189:2012: a pragmatic approach. Clin Chem Lab Med 2017;55:1501\u20138. https:\/\/doi.org\/10.1515\/cclm-2016-0894.","DOI":"10.1515\/cclm-2016-0894"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_169","doi-asserted-by":"crossref","unstructured":"Jacobs, JF, van der Molen, RG, Bossuyt, X, Damoiseaux, J. Antigen excess in modern immunoassays: to anticipate on the unexpected. Autoimmun Rev 2015;14:160\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2014.10.018.","DOI":"10.1016\/j.autrev.2014.10.018"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_170","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Marien, G, Vanderschueren, S. A 67-year-old woman with a systemic inflammatory syndrome and sicca. Clin Chem 2010;56:1508\u20139. https:\/\/doi.org\/10.1373\/clinchem.2010.150789.","DOI":"10.1373\/clinchem.2010.150789"},{"key":"2024012310382636134_j_cclm-2023-0209_ref_171","doi-asserted-by":"crossref","unstructured":"Ma, WT, Chang, C, Gershwin, ME, Lian, ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun 2017;83:95\u2013112. https:\/\/doi.org\/10.1016\/j.jaut.2017.07.003.","DOI":"10.1016\/j.jaut.2017.07.003"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0209\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T10:43:51Z","timestamp":1706006631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0209\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":171,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,1,31]]},"published-print":{"date-parts":[[2023,6,27]]}},"alternative-id":["10.1515\/cclm-2023-0209"],"URL":"http:\/\/dx.doi.org\/10.1515\/cclm-2023-0209","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":["Biochemistry (medical)","Clinical Biochemistry","General Medicine"],"published":{"date-parts":[[2023,3,29]]}}}